3675 MARKET STREET, PHILADELPHIA, PA
Amicus Therapeutics Special Meeting Approves Merger and Compensation Proposals
Announces Full-Year 2025 Financial Results and Corporate Updates
Earnings Release
Enters Definitive Agreement to be Acquired for $14.50 per Share in Cash, Investor Presentation
Announces Third Quarter 2025 Financial Results and Corporate Updates
Investor Presentation
Shareholder votes
Announces First Quarter 2025 Financial Results and Corporate Updates
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Merger Proxy Statement
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
PREM14A